EUVIMEDEUVIMED entdecken
Crossref

Efficacy of short‐term combination of intralymphatic allergen immunotherapy and lokivetmab treatment in canine atopic dermatitis: A double‐blinded, controlled, randomised study

Kelly van Amersfort iD, Johannes C M Vernooij iD, Annette van der Lee

Veterinary Dermatology · 2023

DOI: 10.1111/vde.13165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Veterinary Dermatology, 2023. Verfasst von Kelly van Amersfort und 2 weiteren Autor:innen. Beteiligte Einrichtung: IVC Evidensia Netherlands, Evidensia Dierenziekenhuis Arnhem, Arnhem, the Netherlands. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Dog Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Nextmune.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allergen‐specific immunotherapy (ASIT) is an effective therapy for canine atopic dermatitis (cAD). Intralymphatic immunotherapy (ILIT) is potentially beneficial in decreasing time to clinical effectiveness.

Objective

To compare clinical efficacy of six monthly ILIT injections combined with three monthly injections of lokivetmab (LVM) with monthly LVM monotherapy at Day (D)168. To monitor dogs treated with ILIT for an additional six months of subcutaneous immunotherapy (SCIT). Animals Thirty‐six client‐owned dogs with cAD. Materials and Methods In this double‐blinded, randomised study, dogs received either six monthly injections of ILIT combined with three monthly LVM injections (ILIT group) or six monthly LVM injections (LVM group). Monthly evaluations with pruritus Visual Analogue Scale (pVAS), Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI‐04) and medication scores (MS) were undertaken. Owners completed a Quality of Life (QoL) questionnaire. Treatment success was predefined as ≥50% reduction in pVAS and CADESI‐04 score ≤ 10. After D168, the ILIT group continued with SCIT until subjective assessment at 12 months.

Results

The treatment benchmark at D168 was achieved by 11.1% of the ILIT group and 11.8% of LVM group. A significant decrease in mean pVAS and CADESI scores was observed in both groups ( p < 0.001). The ILIT group had a trend towards higher MS compared to LVM. QoL was better in LVM ( p = 0.01). At 12 months subjective good‐to‐excellent response in 77.8% of dogs in the ILIT/SCIT group was seen. Conclusion and Clinical Relevance The efficacy of this ILIT protocol was comparable with LVM monotherapy at six months. When ILIT was continued with SCIT, a favourable response was seen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicDog DiseasesDogsAnimalsQuality of LifeAntibodies, MonoclonalPruritusDesensitization, Immunologic

Stichwörter der Autor:innen

allergen-specific immunotherapycanine atopic dermatitisintralymphatic immunotherapylokivetmab

Substanzen

lokivetmabAntibodies, Monoclonal

Autor:innen und Institutionen

  • IVC Evidensia Netherlands, Evidensia Dierenziekenhuis Arnhem, Arnhem, the Netherlands.
  • University Utrecht, Utrecht, the Netherlands.

ORCID-Profile: Kelly van Amersfort, Johannes C M Vernooij

Förderung

  • Nextmune

Zitieren

APA

van Amersfort, K., Vernooij, J. C. M., & van der Lee, A. (2023). Efficacy of short‐term combination of intralymphatic allergen immunotherapy and lokivetmab treatment in canine atopic dermatitis: A double‐blinded, controlled, randomised study. Veterinary Dermatology. https://doi.org/10.1111/vde.13165

Vancouver

van Amersfort K, Vernooij JCM, van der Lee A. Efficacy of short‐term combination of intralymphatic allergen immunotherapy and lokivetmab treatment in canine atopic dermatitis: A double‐blinded, controlled, randomised study. Veterinary Dermatology. 2023. doi:10.1111/vde.13165

BibTeX
@article{vanAmersfort2023,
  author = {van Amersfort, Kelly and Vernooij, Johannes C M and van der Lee, Annette},
  title = {Efficacy of short‐term combination of intralymphatic allergen immunotherapy and lokivetmab treatment in canine atopic dermatitis: A double‐blinded, controlled, randomised study},
  journal = {Veterinary Dermatology},
  year = {2023},
  doi = {10.1111/vde.13165}
}
Kostenlos starten →